Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer
Objective: To assess the activity and toxicity of cisplatin and irinotecan alternating with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). Material and Method: Eligibility included chemo-naïve stage IIIB with malignant effusion and stage IV NSCLC patients with measurable dis...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.scopus.com/inward/record.url?eid=2-s2.0-37149053450&partnerID=40&md5=084d5a357dc486f92b8f7b40f356ff89 http://www.ncbi.nlm.nih.gov/pubmed/18181342 http://cmuir.cmu.ac.th/handle/6653943832/2115 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
id |
th-cmuir.6653943832-2115 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-21152014-08-30T02:00:29Z Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer Charoentum C. Thongprasert S. Chewasakulyong B. Euathrongchit J. Sorraritchingchai S. Munprakan S. Objective: To assess the activity and toxicity of cisplatin and irinotecan alternating with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). Material and Method: Eligibility included chemo-naïve stage IIIB with malignant effusion and stage IV NSCLC patients with measurable disease and a good performance status. Twenty-four patients were enrolled into the present study. There were 19 males and 5 females with a median age of 58.5 years and the median performance status was 1. Ninety-six percent had stage IV disease. These patients received cisplatin at 80 mg/ m2 and irinotecan at 200 mg/m2 on day 1, followed by docetaxel at 75 mg/m2 on day 22, in 6-week cycle for a maximum of 3 cycles. Results: Eight out of twenty-two evaluable patients obtained a partial response (36%). The median time to tumor progression was 6 months. The median survival time and 1-year survival rate were 10.4 months and 45% respectively. The most frequent severe toxicities were neutropenia, anemia, and diarrhea. Febrile neutropenia occurred in four patients (16%), and was the cause of treatment-related deaths in two (8%). Other nonhematologic toxicities were mild including nausea, vomiting, and skin rash. Conclusion: Alternating cisplatin and irinotecan with docetaxel, as used in the present study was feasible and demonstrated encouraging efficacy in patients with non-small cell lung cancer. However, this approach appears to be more toxic, especially in myelosuppression, than in previous reports of the sequential use of the similar agents. 2014-08-30T02:00:29Z 2014-08-30T02:00:29Z 2007 Article 01252208 18181342 JMTHB http://www.scopus.com/inward/record.url?eid=2-s2.0-37149053450&partnerID=40&md5=084d5a357dc486f92b8f7b40f356ff89 http://www.ncbi.nlm.nih.gov/pubmed/18181342 http://cmuir.cmu.ac.th/handle/6653943832/2115 English |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
language |
English |
description |
Objective: To assess the activity and toxicity of cisplatin and irinotecan alternating with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). Material and Method: Eligibility included chemo-naïve stage IIIB with malignant effusion and stage IV NSCLC patients with measurable disease and a good performance status. Twenty-four patients were enrolled into the present study. There were 19 males and 5 females with a median age of 58.5 years and the median performance status was 1. Ninety-six percent had stage IV disease. These patients received cisplatin at 80 mg/ m2 and irinotecan at 200 mg/m2 on day 1, followed by docetaxel at 75 mg/m2 on day 22, in 6-week cycle for a maximum of 3 cycles. Results: Eight out of twenty-two evaluable patients obtained a partial response (36%). The median time to tumor progression was 6 months. The median survival time and 1-year survival rate were 10.4 months and 45% respectively. The most frequent severe toxicities were neutropenia, anemia, and diarrhea. Febrile neutropenia occurred in four patients (16%), and was the cause of treatment-related deaths in two (8%). Other nonhematologic toxicities were mild including nausea, vomiting, and skin rash. Conclusion: Alternating cisplatin and irinotecan with docetaxel, as used in the present study was feasible and demonstrated encouraging efficacy in patients with non-small cell lung cancer. However, this approach appears to be more toxic, especially in myelosuppression, than in previous reports of the sequential use of the similar agents. |
format |
Article |
author |
Charoentum C. Thongprasert S. Chewasakulyong B. Euathrongchit J. Sorraritchingchai S. Munprakan S. |
spellingShingle |
Charoentum C. Thongprasert S. Chewasakulyong B. Euathrongchit J. Sorraritchingchai S. Munprakan S. Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer |
author_facet |
Charoentum C. Thongprasert S. Chewasakulyong B. Euathrongchit J. Sorraritchingchai S. Munprakan S. |
author_sort |
Charoentum C. |
title |
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer |
title_short |
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer |
title_full |
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer |
title_fullStr |
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer |
title_full_unstemmed |
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer |
title_sort |
phase ii study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer |
publishDate |
2014 |
url |
http://www.scopus.com/inward/record.url?eid=2-s2.0-37149053450&partnerID=40&md5=084d5a357dc486f92b8f7b40f356ff89 http://www.ncbi.nlm.nih.gov/pubmed/18181342 http://cmuir.cmu.ac.th/handle/6653943832/2115 |
_version_ |
1681419797691105280 |